Suppr超能文献

miRNA 和胰腺导管腺癌中的基因表达。

miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.

机构信息

Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.

Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.

出版信息

Am J Pathol. 2019 Jan;189(1):58-70. doi: 10.1016/j.ajpath.2018.10.005.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease that is mostly diagnosed late in the course of the illness. Unlike other cancers in which measurable successes have been achieved with traditional chemotherapy, targeted therapy, and, recently, immunotherapy, PDAC has proved to be poorly responsive to these treatments, with only marginal to modest incremental benefits using conventional cytotoxic therapy. There is, therefore, a great unmet need to develop better therapies based on improved understanding of biology and identification of predictive and prognostic biomarkers that would guide therapy. miRNAs are small noncoding RNAs that regulate the expression of some key genes by targeting their 3'-untranslated mRNA region. Aberrant expression of miRNAs has been linked to the development of various malignancies, including PDAC. A series of miRNAs have been identified as potential tools for early diagnosis, prediction of treatment response, and prognosis of patients with PDAC. In this review, we present a summary of the miRNAs that have been studied in PDAC in the context of disease biology.

摘要

胰腺导管腺癌 (PDAC) 仍然是一种具有挑战性的疾病,大多数情况下在疾病进程中晚期才被诊断出来。与其他癌症不同,传统化疗、靶向治疗,最近还有免疫治疗已经在这些癌症的治疗中取得了显著的成效,但 PDAC 对这些治疗的反应不佳,常规细胞毒性治疗仅能带来轻微到适度的额外益处。因此,需要基于对生物学的深入了解和鉴定预测及预后生物标志物来开发更好的治疗方法,以满足这一巨大的未满足需求,从而指导治疗。miRNA 是一类小的非编码 RNA,通过靶向其 3'-UTR 区来调节一些关键基因的表达。miRNA 的异常表达与各种恶性肿瘤的发生有关,包括 PDAC。一系列 miRNA 已被确定为 PDAC 患者早期诊断、治疗反应预测和预后的潜在工具。在本文中,我们总结了在 PDAC 疾病生物学背景下研究的 miRNA。

相似文献

1
miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.
Am J Pathol. 2019 Jan;189(1):58-70. doi: 10.1016/j.ajpath.2018.10.005.
2
Differential MicroRNA Expression Profiles as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma.
Biochemistry (Mosc). 2019 May;84(5):575-582. doi: 10.1134/S0006297919050122.
3
MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Oncotarget. 2015 Sep 15;6(27):23323-41. doi: 10.18632/oncotarget.4492.
4
Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Cell Oncol (Dordr). 2017 Apr;40(2):181-192. doi: 10.1007/s13402-017-0315-y. Epub 2017 Feb 15.
7
Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.
Semin Cancer Biol. 2021 Oct;75:153-168. doi: 10.1016/j.semcancer.2020.10.001. Epub 2020 Oct 10.

引用本文的文献

1
Self-emulsifying Nano-PND oral delivery systems of PND1186: In silico modeling for bioavailability estimation.
J Mol Liq. 2025 May 15;426. doi: 10.1016/j.molliq.2025.127161. Epub 2025 Feb 15.
2
The growing field of liquid biopsy and its Snowball effect on reshaping cancer management.
J Liq Biopsy. 2025 Mar 27;8:100293. doi: 10.1016/j.jlb.2025.100293. eCollection 2025 Jun.
3
Identification of key hub genes in pancreatic ductal adenocarcinoma: an integrative bioinformatics study.
Front Bioinform. 2025 Mar 28;5:1536783. doi: 10.3389/fbinf.2025.1536783. eCollection 2025.
4
miRNA profile in pancreatic neuroendocrine tumors: Preliminary results.
Sci Prog. 2025 Jan-Mar;108(1):368504251326864. doi: 10.1177/00368504251326864. Epub 2025 Mar 28.
5
Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine--paclitaxel in advanced pancreatic cancer.
J Liq Biopsy. 2024 Mar 25;5:100152. doi: 10.1016/j.jlb.2024.100152. eCollection 2024 Sep.
6
Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.
Curr Pharm Des. 2025;31(31):2504-2524. doi: 10.2174/0113816128334659241223113743.
8
Using microRNAs Networks to Understand Pancreatic Cancer-A Literature Review.
Biomedicines. 2024 Aug 1;12(8):1713. doi: 10.3390/biomedicines12081713.
9
Dysregulation of a Subset of Circulating and Vesicle-Associated miRNA in Pancreatic Cancer.
Noncoding RNA. 2024 May 1;10(3):29. doi: 10.3390/ncrna10030029.
10
MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications.
Int J Mol Sci. 2024 Mar 31;25(7):3914. doi: 10.3390/ijms25073914.

本文引用的文献

2
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
J Exp Clin Cancer Res. 2018 Apr 3;37(1):76. doi: 10.1186/s13046-018-0739-x.
3
Deciphering microRNA targets in pancreatic cancer using miRComb R package.
Oncotarget. 2018 Jan 8;9(5):6499-6517. doi: 10.18632/oncotarget.24034. eCollection 2018 Jan 19.
4
Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma.
Oncotarget. 2017 Dec 17;9(4):4451-4460. doi: 10.18632/oncotarget.23377. eCollection 2018 Jan 12.
6
MiR-7-5p functions as a tumor suppressor by targeting SOX18 in pancreatic ductal adenocarcinoma.
Biochem Biophys Res Commun. 2018 Mar 18;497(4):963-970. doi: 10.1016/j.bbrc.2018.02.005. Epub 2018 Mar 1.
8
miR-493 inhibits proliferation and invasion in pancreatic cancer cells and inversely regulated hERG1 expression.
Oncol Lett. 2017 Dec;14(6):7398-7404. doi: 10.3892/ol.2017.7178. Epub 2017 Oct 12.
9
MiR-137 functions as a tumor suppressor in pancreatic cancer by targeting MRGBP.
J Cell Biochem. 2018 Jun;119(6):4799-4807. doi: 10.1002/jcb.26676. Epub 2018 Mar 1.
10
Cancer statistics, 2018.
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验